FDA-cleared profile

Genius AI Detection 2.0

Hologic, Inc. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.

Clinical role
Concurrent detection and diagnostic support
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Concurrent adjunctive support only; the interpreting physician must confirm or dismiss findings and remains responsible for interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Compatible digital breast tomosynthesis exams, including 1 mm Clarity HD and 6 mm SmartSlices from the Hologic Envision platform and compatible Hologic Selenia Dimensions exams; DICOM input is described.
  • Who uses it?Intended users: MQSA-qualified interpreting physicians and radiologists
  • What does the software produce?Output: Lesion location, lesion outline, Certainty of Findings confidence score, and an exam-level Case Score, packaged as a DICOM Mammography CAD SR for display on DICOM-compliant review workstations; findings include soft-tissue densities and calcifications.
  • What is its most important limitation?Key limitation: Concurrent adjunctive support only; the interpreting physician must confirm or dismiss findings and remains responsible for interpretation.

Clinical takeaway. Clinical role: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.

Evidence takeaway. Evidence from the reviewed source record: Retrospective multicenter validation included 1,475 subjects from 15 locations with biopsy-proven cancers, benign cases, screening-negative cases, and diagnostic cases; the FDA packet reports no significant ENV-SOC versus ENV-ECS reader-study AUC difference.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Concurrent detection and diagnostic support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Compatible digital breast tomosynthesis exams, including 1 mm Clarity HD and 6 mm SmartSlices from the Hologic Envision platform and compatible Hologic Selenia Dimensions exams; DICOM input is described.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Lesion location, lesion outline, Certainty of Findings confidence score, and an exam-level Case Score, packaged as a DICOM Mammography CAD SR for display on DICOM-compliant review workstations; findings include soft-tissue densities and calcifications.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Screening and diagnostic DBT for symptomatic or asymptomatic women, including implant cases in the described dataset
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
MQSA-qualified interpreting physicians and radiologists
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
Concurrent adjunctive support only; the interpreting physician must confirm or dismiss findings and remains responsible for interpretation.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
Retrospective multicenter validation included 1,475 subjects from 15 locations with biopsy-proven cancers, benign cases, screening-negative cases, and diagnostic cases; the FDA packet reports no significant ENV-SOC versus ENV-ECS reader-study AUC difference.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Retrospective multicenter validation included 1,475 subjects from 15 locations with biopsy-proven cancers, benign cases, screening-negative cases, and diagnostic cases; the FDA packet reports no significant ENV-SOC versus ENV-ECS reader-study AUC difference.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Implant subset sensitivity 76% (95% CI 68%-84%) in 480 cases.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported specificity
Implant subset specificity 67% (95% CI 62%-72%) in 480 cases.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06

AUC difference

-0.0017 AUC difference

  • EndpointENV-SOC versus ENV-ECS reader-study AUC
  • Population1,475 DBT subjects from 15 locations
  • Tested versionGenius AI Detection 2.0 submitted in K243341; build not stated

Sensitivity

76 percent

  • EndpointImplant-subset sensitivity
  • Population480 implant cases
  • Tested versionGenius AI Detection 2.0 submitted in K243341; build not stated

Specificity

67 percent

  • EndpointImplant-subset specificity
  • Population480 implant cases
  • Tested versionGenius AI Detection 2.0 submitted in K243341; build not stated

Genius AI Detection 2.0 multicenter DBT reader study

  • DesignRetrospective multicenter reader study and standalone validation
  • Population1,475 subjects from 15 locations, including 200 biopsy-proven cancers, benign cases, screening-negative cases, and diagnostic cases
  • Scopeexact submission
  • Tested versionGenius AI Detection 2.0 submitted in K243341; build not stated
  • Samplen=1475
  • Sites15
  • IndependenceIndependence not established

K243341

Two MQSA radiologists interpreted cases; a separate implant subset contained 480 cases.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Compatible digital breast tomosynthesis exams, including 1 mm Clarity HD and 6 mm SmartSlices from the Hologic Envision platform and compatible Hologic Selenia Dimensions exams; DICOM input is described.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K243341: Genius AI Detection 2.0

  2. Routing

    Source context, not route validation: The submission describes DICOM Mammography CAD SR output for DICOM-compliant review workstations and worklist use; local Hologic platform, workstation, and version compatibility require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K243341: Genius AI Detection 2.0

  3. AI processing

    Source context, not route validation: The exact FDA package describes the subject device's deployment as a stand-alone computer, with a softcopy workstation as the output device. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Features and Subject Device Predicate Device Difference and" … "Output Device Softcopy Workstation Same N/A Deployment Stand-alone computer Same N/A". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) K243341: Genius AI Detection 2.0

  4. Returned objects

    Source context, not route validation: Lesion location, lesion outline, Certainty of Findings confidence score, and an exam-level Case Score, packaged as a DICOM Mammography CAD SR for display on DICOM-compliant review workstations; findings include soft-tissue densities and calcifications.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K243341: Genius AI Detection 2.0

  5. Viewer/worklist/report

    Unresolved route: Lesion location, lesion outline, Certainty of Findings confidence score, and an exam-level Case Score, packaged as a DICOM Mammography CAD SR for display on DICOM-compliant review workstations; findings include soft-tissue densities and calcifications.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K243341: Genius AI Detection 2.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes the subject device's deployment as a stand-alone computer, with a softcopy workstation as the output device. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Features and Subject Device Predicate Device Difference and" … "Output Device Softcopy Workstation Same N/A Deployment Stand-alone computer Same N/A". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The submission describes DICOM Mammography CAD SR output for DICOM-compliant review workstations and worklist use; local Hologic platform, workstation, and version compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-06
Security
Hologic's Breast and Skeletal Products Cybersecurity page states patch validation for Hologic Breast and Skeletal Health systems, MDS2 forms availability, and published security advisories with product impact analyses (including Libwebp, MOVEit, Log4j and Axeda advisories).
  • Product family
  • Checked 2026-10-26

Vendor statement, not an attestation. Page scope is Hologic's Breast and Skeletal Health division; this entry is a mammography/DBT product within that division. Exact-release scope is not established.

Monitoring
Hologic's Breast & Skeletal Products cybersecurity page states that it provides validated patches, MDS2 forms and security advisories with product impact analyses, with published advisories covering Libwebp, MOVEit, Log4j and Axeda.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page scopes to Hologic Breast & Skeletal products generally and does not scope this process to any specific product release; exact-release scope is not established.

DICOM CAD SR workflow

The exact submission packages findings as a DICOM Mammography CAD SR for DICOM-compliant review workstations and worklist display.

exact submission · checked 2026-09-06

Hologic family workstation context

Hologic's official Genius family page describes display through SecurView 12.0 and worklist workflow; exact K243341 deployment and local compatibility require confirmation.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243341
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-07-31
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Hologic Genius AI Detection reimbursement CPT mammography"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Hologic's 2026 Mammography Coding Guide (MISC-03286 REV 016) was read; it lists CPT 77065-77067 and does not name Genius AI Detection, so it is kept as a lead. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K243341: Genius AI Detection 2.0

    U.S. Food and Drug Administration - Published 2025-07-31 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Genius AI Detection 2.0 model card (K243341)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Genius AI Detection technology official product page

    Hologic - Accessed 2026-09-07

    Scope: productFamilyWorkflow, implementationCapabilities

  8. Hologic: Breast & Skeletal Products Cybersecurity

    Hologic - Accessed 2026-10-26

    Scope: security

Research history

  1. K243341 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23
FDA-cleared K253796

Lunit INSIGHT DBT (V1.2)

Lunit, Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-03-26
FDA-authorized DEN240047

Allix5

Clairity, Inc.

Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-05-30

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history